Vorinostat in solid and hematologic malignancies

David S. Siegel(Hackensack Meridian Health), Syed Rizvi(Merck (Japan)), Evanthia Galanis(Mayo Clinic in Arizona), Victoria M. Richon(Memorial Sloan Kettering Cancer Center), J. Garcia‐Vargas(San Antonio College), Mohamad A. Hussein(University of South Florida), César Sanz-Rodrı́guez(Merck Biopharma Co., Ltd. (Japan)), Francisco Robert(University of Alabama at Birmingham), Chandra P. Belani(Pennsylvania State University)
Journal of Hematology & Oncology
July 27, 2009
10.1186/1756-8722-2-31
Cited by 204

Related Papers

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group
|Journal of Clinical Oncology|2003|943
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721